TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01152541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin/Dextran
Description: Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic Riboflavin
Description: Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
Study: NCT03701009

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CBD stone removal via lithotripsy
Description: Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline 50ml
Description: If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline +50ml
Description: If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
Study: NCT01771783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RI-ACEI-ARB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RI-ACEI-ARB
Study: NCT02863848

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OraftiR inulin-type fructans

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrin
Study: NCT02969018

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03428373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 10mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: ASA 81mg
Study: NCT00868387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy-restricted, CHO-restricted diet
Description: carbohydrate content of the diet \< 40% Frequency: daily Duration: 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: energy-restricted, CHO-rich diet
Description: carbohydrate content of diet \> 55% Frequency: daily Duration: 12 months
Study: NCT00777543

Intervention type: OTHER
Group type: OTHER
Intervention: ferulic acid
Description: Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ferulic acid
Description: Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treated bran bread
Description: This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
Study: NCT01763177

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen mask 40% 8 LPM for 30 minutes
Study: NCT03622801

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
Study: NCT01494532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropinirole/L-dopa
Description: Ropinirole as adjunctive therapy with L-dopa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/L-dopa
Description: Placebo as adjunctive therapy with L-dopa
Study: NCT04513587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based weight loss model
Description: Methods of cognitive behavioral psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment as usual
Study: NCT04839276

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection Laryngoplasty with Platelet-rich Fibrin and Autologous Fat
Description: Injection Laryngoplasty with a combination of Platelet-rich Fibrin (PRF) and Autologous Fat. The PRF was made by taking 10 mL of peripheral blood from a healthy donor. Blood is then put inside the tube from the Regen lab kit. The tube was centrifuged with a force of 1,500 g (3000 rpm) for 5 minutes producing platelet-rich plasma (PRP). 4 mL of the aforementioned PRP was transferred to a 10 mL test tube, 1 M CaCl2 was added with a micropipette until final concentration of 25 mM was, reached producing PRF. Autologous fat harvested from the patient's abdomen was then mixed with the PRF solution to create the filler for injection laryngoplasty procedures. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection Laryngoplasty with Autologous Fat
Description: Injection Laryngoplasty with autologous microlobular fat harvested from the patient's abdominal fat. Lidocaine was infiltrated under the umbilicus and then an incision was made in the area followed by fat removal using scissors. The fat was cleaned with 0.9% NaCl solution and then sheared into microlobular form. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
Study: NCT04975035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolodine
Description: Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
Study: NCT02659358

Intervention type: DEVICE
Intervention: Fitbit Charge HR®
Description: A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
Study: NCT03158467

Intervention type: OTHER
Intervention: Surveys
Description: Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.

Intervention type: OTHER
Intervention: Surveys
Description: Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
Study: NCT04365153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab Injection 600mg
Description: Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab Injection 300mg
Description: Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 250 mL of 5% dextrose infused IV over 2 hours
Study: NCT04167267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet A
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet A
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet B
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet B
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
Study: NCT01724372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic
Study: NCT02544672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoelectric Elbow-Wrist-Hand orthosis
Description: An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
Study: NCT03675269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBOT
Description: Standard practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound care
Description: Standard wound care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: Standard wound care
Study: NCT00112957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rV-NY-ESO-1 vaccine
Description: Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10\^7 PFU) on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rF-NY-ESO-1 vaccine
Description: Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10\^7 PFU) on Days 29, 57, 85, 113, 141, and 169.
Study: NCT04677257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI, invasive coronary physiology and CMR
Description: Patients with acute STEMI will undergo invasive assessment of coronary physiology (IMR and CFR) following successful primary PCI and CMR within a week of the acute event
Study: NCT01807455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital Lidocaine
Study: NCT04057768

Intervention type: DEVICE
Group type: OTHER
Intervention: Venus Viva
Description: The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
Study: NCT02935387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taper
Description: Taper

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taper
Description: Taper
Study: NCT02646163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2055
Description: (First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks.
Study: NCT00149643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
Study: NCT02412943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma
Description: Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
Study: NCT02313155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of TAK-850
Description: TAK-850 0.5 mL, Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of TAK-850
Description: TAK-850 0.5 mL, Intramuscular injection
Study: NCT00689936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and low-dose dexamethasone
Description: Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression
Study: NCT00777543

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: wholegrain bread
Description: The control is the wholegrain bread enriched with bran that has not been pretreated
Study: NCT03960528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: 20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
Study: NCT03323749

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: elamipretide
Description: 40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: 40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: elamipretide open label treatment
Description: 40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
Study: NCT03071718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:~* 7 portions of milk or yogurt plus whole grain cereals,~* 7 portions of nuts (30g)~* At least 3 portion of absolute legumes~* 14 portions of vegetables~* 21 portions of fruit~* 4 portions of whole grain pasta~* 3 portions of whole grain pasta with vegetables or legumes~* 7 portions of whole grain bread~* 3 portions of fish~* Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
Study: NCT04468477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6 Lead ECG
Description: Patients will be assessed with the Kardiamobile device.
Study: NCT00689936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
Description: lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan, Prednisone and Thalidomide
Description: Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
Study: NCT02749825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelstar
Description: As labeled
Study: NCT01979107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive action by the general practitioner
Description: Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results.
Study: NCT00826748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
Study: NCT02749825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron
Description: As labeled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: As labeled
Study: NCT02819817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe Vera Gel
Description: The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound gel
Description: The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
Study: NCT03026803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study: NCT01567410

Intervention type: OTHER
Group type: OTHER
Intervention: e-learning
Description: Braden scale and pressure ulcer classification
Study: NCT04173793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies
Study: NCT01567410

Intervention type: OTHER
Group type: OTHER
Intervention: traditional classroom training
Description: Braden scale and pressure ulcer classification
Study: NCT03947554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HRG80 Panax ginseng
Description: Panax ginseng containing 63.4 mg ginsenosides

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Panax ginseng
Description: Panax ginseng containing 19.6 mg ginsenosides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 800 mg excipient
Study: NCT02708303

Intervention type: OTHER
Intervention: Mayo Clinic Foregut Surgery Report Card Questionnaire
Description: Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research.
Study: NCT02553668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen (FiO2 1,0)
Description: Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facemask
Study: NCT03911843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 supplementation
Description: Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Cholecalciferol 1000 IU/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: Cholecalciferol 1000 IU/die
Study: NCT02975583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorapaxar
Description: 2.08 mg oral tablet daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral tablet daily
Study: NCT02372214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training
Description: Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
Study: NCT00280670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Cognitive behavioral therapy for children with autism and anxiety.